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Methods fordetecting microbial antigens in clinical specimens offer an alternative to culture in
the diagnosis ofsome sexually transmitted diseases. Developers ofthe immunologic methods are
faced with a number of problems in evaluating the new tests. Traditionally, these tests are
compared to culture as the "gold standard." Unfortunately, culture for Neisseria gonorrhoeae or
Chiamydia trachomatis-the two agents most commonly sought-is considerably less sensitive
than 100 percent. Immunologic methods may appear to produce false positives when the paired
specimens are actually false-negative cultures. Another source of discordant results is sampling
variation. These considerations, however, will not account for all false-positive results. Even the
best non-culture methods have a low rate offalse-positive results. Ifa new test has a specificity of
97 percent, it, by definition, yields approximately 3 percent false-positive reactions. In low-
prevalence settings this false-positive rate will create problems in interpreting the results. For
example, in a population with 3 percent prevalence of infection, a positive result in a 97 percent
specificity test could only have a predictive value of 50 percent. Most testing for STD agents is
performed in low-prevalence settings. None of the currently available immunodiagnostic proce-
dures has a performance profile that suggests it will be satisfactory for diagnostic use in the
low-prevalence setting.
The purpose ofthis article is to discuss immunologic methods ofdiagnosing sexually
transmitted disease (STD); this will not be a review ofthe literature. The focus will be
on evaluation ofthe new methods, what can be expected from such tests, and how they
should be used. Much of the article will be based on the experience of the author's
laboratory in evaluation of immunologic methods for diagnosing gonococcal and
chlamydial infections.
We will simply accept the premise that commercially available reagents for
detecting antigens of Neisseria gonorrhoeae or Chlamydia trachomatis in clinical
specimens dowork. The basicquestions are, "How well dothey work?" and "How may
these tests best be used?" At this writing, there are two procedures that are available:
immunofluorescent (FA) procedures, usually using monoclonal antibodies and requir-
ing microscopic evaluation, or enzyme immunoassay (EIA) procedures where color
indicator reactions may be read either visually or by a spectrophotometer to signal the
presence ofa detected antigen.
EVALUATION OF THE NEW TEST-HOW GOOD IS THE
"GOLD STANDARD"?
Non-culture methods are usually compared to culture as the gold standard for
diagnosing infection [1,2]. When a new test is being evaluated, it is typical to express
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TABLE 1
Evaluation of a Non-Culture Diagnostic Test
Culture
+ a b (a + b)
New Test
_ c d (c + d)
(a (b +
+c) d)
Element Formula Definition
Sensitivity a/(a + c) Ability oftest to identify people who are
culture-positive
Specificity d/(d + b) Ability oftest to identify people who are
culture-negative
Predictive Value (+) a/(a + b) Probability ofbeing culture-positive
given a positive test
Predictive Value (-) d/(c + d) Probability ofbeing culture-negative
given a negative test
False positives b Culture-negative specimens that test
positive
False negatives c Culture-positive specimens that test neg-
ative
Agreement: (a + d)/(a + b + c + d)
the performance pattern ofthe test in terms ofsensitivity, specificity, predictive value
ofa positive and negative test and agreement seen when the new test is compared tothe
gold standard (Table 1).
The gold standard is usually assumed to have a sensitivity and specificity of 100
percent. In other words, in the gold standard test there are neither false positives nor
false negatives. Unfortunately, that is a false assumption. It is true that, with correct
laboratorytechnique (i.e., nocross-contamination and correct identification offermen-
tation patterns and so on), that there will be no false positives generated by culture.
However, there can be a problem with sensitivity of culture. It is clear that culture
mpthpdsforchlamydial infections orgonococcal infections do notdetect 100 percent of
infections.
With gonococcal infections, culture failure may be caused by vancomycin suscepti-
bility; ultimately there is a potential problem with susceptibility to any antibiotic that
may be included in a selective medium [3].
Obviously there are sampling problems, caused in part by temporal variations in the
number oforganisms that are present in clinically relevant sites. Thus, when samples
are collected at a time of low-level infection, the infection may not be detected.
Collection of multiple swabs or sampling ofmultiple sites has been shown to increase
positivity rates [4,5]. For the sake of convenience, it has been recommended that for
gonococcal culture two swabs be collected from the cervix and processed as a single
specimen [6]. For chlamydial culture, increased isolation rates are seen if a cervical
and a urethral swab are collected and processed as one specimen. These seem
reasonable approaches and are realistic compromises with culturing multiple swabs
from the cervix, rectum, and so forth. However, if such measures of maximizing
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TABLE 2
Repeat Cervical Culture in Untreated Gonorrhea
Day ofCycle No. Positive/No. Tested (%)
1-5 231/290 (80)
>6 884/1,199 (74)
Total 1,115/1,489 (75)
Data from [7]
culture results are necessary, it attests to the potential lack of reliability of a single
swab culture and questions the assumption that matched swab specimens always yield
the same results.
One way ofassessing the sensitivity ofculture is to determine the reproducibility of
positive cultures after short intervals. One such study, ofrepeatcultures ofwomen who
had been culture-positive for N. gonorrhoeae and were called back for therapy, found
approximately 75-80 percent positivity at the second culture [7] (Table 2). While it is
likely that some ofthe negatives were due to spontaneous clearance ofthe organism, it
is far more likely that most represent false-negative culture results.
It is probable that culture for chlamydial infection is equally insensitive. Oriel and
Ridgway found that 83 percent of women who had been identified as source contacts
for men with chlamydial urethritis yielded the organism from thecervix [8]. It is likely
that the majority of the negative attempts in that study were also culture misses. In a
longitudinal study of pregnant women in San Francisco, we found approximately 75
percent ofcultures are positive when untreated women areretested. Mostofthe women
who had had negative attempts were culture-positive when third or fourth isolation
attempts were performed. Thus, it is likely that for these asymptomatic women, whose
cervical infections were detected during routine screening, the sensitivity ofculture is
only about 75 percent.
The relative insensitivity of culture presents a dilemma for anyone evaluating a
non-culture method fordiagnosis. In typical analysis the "b" cell (Table 1) is described
as the false positives by the non-culture method. But when culture is <100 percent
sensitive, that cell in fact could reflect increased sensitivity ofthe non-culture method.
Since any non-culture method is likely to have a certain rate offalse positives, the "b"
cell is likely to contain a summation of missed cultures ("false" false positives) and
non-culture method false positives ("true" falsepositives). Currently there is no wayof
assessing this distribution within the "b" cell, although one could apply a series of
different tests and accept any two as indicating a positive result, but that would
probably only be valid if the tests were based on completely different criteria. It is
likely that the problem of culture sensitivity becomes more important in screening
asymptomatic individuals.
WHICH GOLD STANDARD?
Another question that must be dealt with when evaluating a new test is: What gold
standard is being used? We have already seen that culture is <100 percent sensitive. It
is imperative for an evaluator to describe carefully the culture procedure being used.
The importance ofdefining that gold standard can be seen in Table 3, which compares
different methods for isolating C. trachomatis. Thesedata weregenerated in screening
asymptomatic women for chlamydial infection ofthecervix. In that setting one can see
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TABLE 3
Comparison of Isolation Methods for Chiamydia trachomatis
Method
(All Blind Pass) % Isolates Obtaineda
96-well plate; iodine 48
96-well plate; fluorescent
antibody 73
Vials; iodine 92
'Cervical screening, asymptomatic population, 48/618 (7.8 percent)
positive in any of the three methods; inoculum centrifuged onto
monolayers (2,700 g for one hour), cycloheximide-treated McCoy
cells, blind passage
that the use of96-well microtiter plates is far more sensitive when the monolayers are
stained with an FA procedure fordetection ofinclusions than when iodinestain is used.
However, the useofone-dram vials (with a larger surface area ofcell monolayer), even
when iodine stain is used, is more sensitive than any microtiter plate procedure. Most
discrepancies were found with specimens that had <10 inclusions per coverslip in the
one-dram vials. If more agent was found, the specimens tended to be positive by any
method.
We ran parallel tests with plates and vials, splitting the inoculum between the two
systems. The comparative tests were performed over several months while we
evaluated different staining methods and different procedures for blind passage. No
matter what variables we used, the vials were always superior. In one parallel series,
other than that shown in Table 3, we found that in screening asymptomatic women we
recovered Chiamydia from 93 of 1,229 (7.6 percent) cervical specimens. Ninety ofthe
specimens were positive in vials, while 69 were positive in plates. Of 52 specimens that
yielded <10 inclusions per vial coverslip, 19 (37 percent) were missed in the plates. Of
the total 21 misses in the plates, 19 (90 percent) were from the low-titer inoculum
group.
When FA techniques were used to stain the coverslips in vials, the procedure was
even more sensitive. In some laboratories it has been found that all positive chlamydial
cultures could be detected in the first pass when the more sensitive FA procedure was
used, but that has not been our experience in screening asymptomatic individuals. A
second pass, even when FA was used for staining both primary culture and passage,
resulted in 13 percent more isolates being obtained after the passage. Thus, one must
accept the gold standard for chlamydial culture, at the moment, to be the use of
one-dram vials, a blind passage, and the FA technique for staining inclusions. The
MicroTrak® (Syva Co., Palo Alto, CA) Chiamydia trachomatis Culture Confirmation
Test is the commercially available reagent for which there is an extensive published
experience. It may be considered the reagent of choice [9]. Other FA reagents for
staining inclusions in cell culture are available (Ortho Chlamydia Direct Identification
Test®; Ortho Diagnostic Systems, Inc., Carpinteria, CA) but have not been as well
evaluated.
This is not tosay that otherprocedures, such as using microtiter plates or notdoing a
blind passage, are inappropriate. If our studies had been performed in an STD clinic,
where more symptomatic patients were being tested, the differences in procedure
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would not be as great. Selecting an asymptomatic screening setting artificially
exaggerates the differences in sensitivity. Whether or not a blind pass is useful depends
on a cost-benefit analysis. In symptomatic patients we find that approximately 10
percent of isolates are obtained in the second pass. Increasing the recovery rate of
chlamydiae from 20 percent to 22 percent in a population may well be desirable, but it
is probably far more practical to test another 80 patients and detect another 16 (20
percent) infections rather than do the blind pass to identify another two infections. In
screening asymptomatic women, however, we find that up to 40 percent of the isolates
are detected in the blind pass.
The above discussions obviously stress the importance of recognizing the fallibility
of the gold standard but also the necessity for adequate description. It should lead a
readerofthe literature to a better understanding ofhow new tests are truly performing.
If a non-culture method for detecting chlamydial infection is being compared to
culture in an asymptomatic population and no blind passage is done, one can predict
that the results will be markedly skewed by the relative insensitivity of the gold
standard. If the tests agree, then the non-culture assay is relatively insensitive as well.
If there are many false positives detected by the non-culture assay, one must wonder
how many ofthose false positives would become true positives with a second pass (i.e.,
being moved from the "b" cell to the "a" cell in Table 1).
ANALYSIS OF THE EVALUATION; GONOZYME AS AN EXAMPLE
The application of predictive value analysis is crucial in determining how a test
should be used. It is usually more important to stress the PV (+). With STD, in most
clinics, PV (-) and agreement are always high, because most patients do not have the
disease and the majority ofthe population is in the "d" cell (Table 1). For example, if
the population has a true prevalence of 10 percent as they enter a clinic, someone
standing at the door saying, "You don't have it," will be in agreement with culture >90
percent ofthe time and the predictive value ofthat negativejudgment will also be >90
percent.
Obviously there are other practical considerations. When we analyzed the Gono-
zyme@ (Abbott Laboratories, Chicago, IL) test for diagnosing gonococcal infections in
the male urethra, we found that the test performed very well, but it did not present any
marked improvement over the inexpensive and rapid Gram stain procedure (Table 4).
Thus, there appeared to be no reason to recommend that test for diagnosis of
symptomatic male urethritis.
However, Gram stain is not as useful for cervical infection, where improved
diagnostic tests are needed. The findings with Gonozyme in diagnosing gonococcal
infection ofthe cervix are presented in Table 4. The test obviously performs reasonably
well. The 87 percent sensitivity leaves something to be desired in an STD setting, but
the performance profile is quite a reasonable one in a high-prevalence setting.
However, the 98 percent specificity which looks like a very good result (indeed, how
much more can one expect from developers ofsuch a test), severely restricts the use of
the test in a low-prevalence setting. The results expected ifa test with that performance
profile is used in a1 percent prevalence population are shown in Table 5. It becomes
obvious that more false-positive results are being generated than are true positives.
This clearly creates a problem because the clinician has a dilemma in how to manage
these patients. Should they be treated? Should partners be treated routinely? Should
447JULIUS SCHACHTER
TABLE 4
Diagnosis of Gonococcal Infection by Gonozyme and Culture
A. Gonozyme in male urethritis
Culture
EIA + 70 0
- 5 42
Prevalence = 64 percent PV (+) = 100 percent
Sensitivity = 93 percent PV (-) = 89 percent
Specificity = 100 percent Agreement = 96 percent
B. Gonozyme in cervical infection
Culture
EIA + 33 1
- 5 47
Prevalence = 44 percent PV (+) = 97 percent
Sensitivity = 87 percent PV (-) = 90 percent
Specificity = 98 percent Agreement - 93 percent
Data from [10]
these positive results be reported to the public health officials as diagnosed cases of
gonorrhea? Obviously these are serious questions, and clinicians would prefer not to
have to deal with them. A clinician wants a diagnostic test to provide answers, not
create further problems.
Of course, a clinician can always say, "Why bother generating this type of
analysis?" when the test was actually evaluated in high-prevalence settings. But, in
fact, that analysis was not a philosophical endeavor but is truly representative of the
way some of these tests are applied. For example, the most recent available data on
cervical cultures for gonorrhea performed in this country is for the year 1983 [11]
(Table 6). Eighty-nine percent of cultures for gonorrhea are performed in settings
other than STD clinics. The prevalence of gonococcal infection in STD clinics was
approximately 17 percent, but it was only 2.5 percent in the setting where most tests
are performed. A test with theperformance characteristics described abovewould have
a positive predictive value of only 53 percent in other than STD clinics. Such a
predictive value may provide information of some use to the clinician; it may indicate
the need for a second test, perhaps by culture. That depends on the cost ofculture, the
dangers of not treating, and the various dangers of different intervention modalities.
TABLE 5
Results Expected Using Gonozyme and Culture in Screening 10,000
Women with a One Percent Prevalence of Cervical Gonorrhea
Culture Results
Gonozyme Results Positive Negative
Positive 87 205
Negative 13 9,695
Data from [10]
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TABLE 6
Gonorrhea Cultures Performed on Females in the United
States-1983
No. Positive/No. Tested (%)
VD Clinics 148,429/885,231 (16.8)
Other 170,673/6,835,629 (2.5)
Total 319,102/7,720,860 (4.1)
Data from [11]
The latter dangers may be medical, financial, or social. The obvious question is
whether any test with this performance profile should be used in this low-prevalence
setting.
EVALUATION OF MICROTRAK@ DIRECT SPECIMEN TEST
Our evaluation ofthe FA procedure using monoclonal antibodies specific for major
outer membrane antigen of C. trachomatis has been somewhat less satisfactory than
the published experience. Published data have indicated a sensitivity of >90 percent
and specificity levels of approximately 98 percent [12]. Some results have been far
better than that, with virtual perfect concordance. Some researchers have claimed
sensitivities ofwell over 100 percent, as compared to culture. They have assumed that
because a monoclonal antibody was being used, that all reactions were truly specific
and that all positives not confirmed by culture results represented culture misses. That
type of evaluation is naive. The FA reagent is a superb one. It stains chlamydial
particles brightly and there is very little nonspecific fluorescence in the clinical
specimen. Certainly it is far superior to the polyclonal reagents that had been
previously used, but there are true false-positive results obtained with this reagent.
Some small round bacteria have been observed to stain. We have also seen persistence
of FA staining that appears to be elementary body staining, after tetracycline therapy
and in the absence of symptoms. The ultimate source of these confounding reactions
awaits elucidation, but suffice it to say they do exist, and the rates must be defined.
Our experience is summarized in Table 7. Here too we were testing asymptomatic
individuals and that works against the performance profile of a non-culture method.
Sensitivity of the FA procedure was 70 percent. The 94 percent specificity obviously
reflects both false positives and culture misses. One problem identified in our
evaluation was that 15 percent of the smears for the FA procedure were inadequate
TABLE 7
MicroTrak@ Compared to Culture for Chlamydial Cervical
Infection
Element No. Positive/No. Tested (%)
Prevalence by culture 90/655 (13.7)
Agreement 592/655 (90)
FA sensitivity 63/90 (70)
FA specificity 529/565 (94)
PV (+)FA 63/99 (64)
PV (-) FA 529/556 (95)
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(sufficient numbers of cells could not be seen microscopically). However, we have no
way of knowing whether a specimen submitted for an isolation attempt is adequate.
Where the FA smear was appropriately collected and positive, we could have what
appears to be a false positive, if the parallel culture specimen was not adequate. The
reverse could not happen, because we would see that the smear was inadequate and
exclude the paired specimen from the analysis.
It is likely that the FA procedure will be more efficient in diagnosing symptomatic
infection. In a small study of such patients we found sensitivity of 80 percent,
specificity of97 percent (data not shown). We concluded that isolation was the method
of choice for diagnosing chlamydial cervical infection. If culture is not available, the
FA procedure is useful in testing high-prevalence symptomatic populations.
WHERE SHOULD THESE TESTS BE USED-FUTURE DEVELOPMENTS
There are obviously a number ofsettings in which non-culture methods ofdiagnosis
are desirable: where culture methods are expensive or difficult to perform, or are not
readily available, or where transport problems may result in loss of viability. In
addition, non-culture methods may be suited for screening. Manufacturers must
decide whether these tests are to be used for diagnostic tests or for screening. For the
latter purpose a clinician would want high sensitivity (to identify all positives) and any
problems with specificity could be dealt with by a more specific confirmatory test. The
latter could be another test (culture?) or perhaps a different configuration ofthe same
antigen detection method.
Obviously the manufacturers will endeavor to improve the performance of their
products. We, as scientists, can hasten that process by refusing to accept inadequate
performance characteristics.
Non-culture methods ofdiagnosis can have a great public health impact. They hold
the promiseofmaking accuratediagnosis ofgonococcal and chlamydial infection more
readily available. These methods may allow us to test populations that currently escape
surveillance. For example, we have spent much effort in screening asymptomatic
women and trying to define risk factors for chlamydial infection [14]. Wecan generate
this information because women routinely have pelvic examinations and cervical
specimens are readily obtainable. In some of our studies we find infection rates of
15-25 percent in women who are not coming to clinics becauseofmedical problems but
are appearing for routine examinations (Pap smears, birth control advice, and so on).
When such women are identified, obviously they and their partners (when available)
are treated. However, we never deal with the male population on a routine screening
basis because there are no noninvasive methods for sampling the urethra to detect
chlamydial or gonococcal infections. One obvious possibility would be to test urine. A
review on the use ofurine in diagnosing STD concluded that it might be an appropriate
specimen for use in screening asymptomatic males for gonococcal infection [15]. A
study of asymptomatic adolescent males found that pyuria in first-catch urine
specimens had a high predictive value for recovery of chlamydiae or gonococci from
urethral swabs [16]. Obviously it would be desirable if the same specimen could be
used for both screening (pyuria) and diagnosis (culture or antigen detection). Ifurine
were an appropriate holding medium for gonococci and Chlamydia, it might be
possible to screen first-catch urines for presence ofpolymorphonuclear leukocytes and
then do the appropriate cultures on it. However, results obtained with urine as a
holding medium for gonococcal specimens have been variable and urine or urine
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TABLE 8
Gonozyme@ on Urine Sediment versus Urethral Swab Culture
Culture
EIA + 25 2
EIA - 2 156
Agreement = 98 percent Prevalence = 15 percent
Sensitivity = 93 percent PV (+) = 93 percent
Specificity = 99 percent PV (-) = 99 percent
sediment are clearly not the specimens of choice for diagnosing chlamydial infection
[17]. It may well be that antigen detection offers a viable alternative. Rudrik and
colleagues have shown that gonococcal antigens could be detected by the Gonozyme
test in urine specimens from men with gonococcal urethritis [18]. We too have been
evaluating this approach (Table 8) and find that the Gonozyme test has reasonably
high sensitivity, specificity, and predictive value in diagnosing gonorrhea by detection
ofgonococcal antigen in urine sediment. The data presented in Table 8 are preliminary
results taken from an ongoing study where we are assessing different methods of
detecting gonococcal and chlamydial antigens in first-catch urine from men. Clearly
this represents one potential use of immunologic tests for chlamydial or gonococcal
infection.
CONCLUSIONS
In summary it is clear that immunologic methods fordetecting microbial antigens in
specimens being studied for STDs do work. It is equally clear, however, that none of
the currently available tests has a performance profile that allows any real degree of
confidence in applying the test in a low-prevalence setting. The tests seem best suited
for use in high-risk populations and symptomatic individuals. The non-culture methods
of diagnosis obviously must be compared against culture as a gold standard, but it is
imperative that those planning to apply these tests simply not accept the numbers
presented to them in the literature. One must be aware of the real performance of
culture and of the potential poor value of the gold standard. If a culture method is
really only 75 percent sensitive and a non-culture method is 90 percent as sensitive as
the culture method, we are now accepting a real sensitivity of 65 percent. We must
insist on better.
REFERENCES
1. Dans PE, Rothenberg R, Holmes KK: Gonococcal serology: How useful and how much? (Editorial). J
Infect Dis 135(2):330-333, 1977
2. Vecchio TJ: Predictive value of a single diagnostic test in unselected populations. New Eng J Med
274:1171-1173, 1966
3. Brorson JE, et al: Vancomycin-sensitive strains ofNeisseria gonorrhoeae: A problem for the diagnostic
laboratory. Br J Vener Dis 49:452, 1973
4. Paavonen J: Chlamydia trachomatis-induced urethritis in female partners of men with nongonococcal
urethritis. Sex Transm Dis 6(2):69-71, 1979
5. Chapel TA, Smeltzer M: Culture of urinary sediment for the diagnosis of gonorrhea in women. Br J
Vener Dis 51:25-27, 1975
6. Judson FN, Werness BA: Combining cervical and anal-canal specimens for gonorrhea on a single
culture plate. J Clin Microbiol 12(2):216-219, 1980452 JULIUS SCHACHTER
7. McCormack WM, Reynolds GH, Cooperative Study Group: Effect of menstrual cycle and method of
contraception on recovery ofNeisseria gonorrhoeae. JAMA 247(9):1292-1294, 1982
8. Oriel JD, Ridgway GL: Studies ofthe epidemiology ofchlamydial infection ofthe human genital tract.
In Chlamydial Infections. Edited by P-A Mardh, KK Holmes, JD Oriel, P Piot, J Schachter.
Amsterdam, Elsevier Biomedical, 1982, pp 425-428
9. Stamm WE, Tam M, Koester M, Cles L: Detection ofChlamydia trachomatis inclusions in McCoy cell
cultures with fluorescein-conjugated monoclonal antibodies. J Clin Microbiol 17(4):666-668, 1983
10. Schachter J, McCormack WM, Smith RF, Parks RM, Bailey R, Ohlin AC: Enzyme immunoassay for
diagnosis ofgonorrhea. J Clin Microbiol 19(l):57-59, 1984
11. Centers for Disease Control, Division ofSexually Transmitted Diseases: STD Statistics 133: 50, Table
36. Atlanta, GA, Statistics Services Section, 1985
12. Tam MR, Stamm WE, Handsfield HH, Stephens R, Kuo C-C, Holmes KK, Ditzenberger K, Crieger
M, Nowinski RC: Culture-independent diagnosis ofChlamydia trachomatis using monoclonal antibod-
ies. New Eng J Med 310(18):1146-1150, 1984
13. Lipkin E, Moncada J, Schachter J: Comparison of monoclonal antibody staining and culture in
diagnosing cervical chlamydial infection. In preparation
14. Schachter J, Stoner E, Moncada J: Screening for chlamydial infections in women attending family
planning clinics: Evaluations ofpresumptive indicators for therapy. W J Med 138(3):375-379, 1983
15. Schachter J: Urine as a specimen for diagnosis ofSTD. Am J Med 28:93-97, 1983
16. Adger H, Shafer M-A, Sweet RL, Schachter J: Screening for Chlamydia trachomatis and Neisseria
gonorrhoeae in adolescent males: Value of first catch urine examination. Lancet ii(8409):944-945,
1984
17. Smith TF, Weed LA: Comparison of urethral swabs, urine and urinary sediment for the isolation of
Chlamydia. J Clin Microbiol 2(2):134-135, 1975
18. Rudrik JT, Waller JM, Britt EM: Efficacy ofan enzyme immunoassay with uncentrifuged first-voided
urine for detection ofgonorrhea in males. J Clin Microbiol 20(3):577-578, 1984